Advances in Neovascular Retinal Disease: A Case-Based, Data-Driven Guide to Treatment
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Expiration Date: November 30, 2024
Time to Complete Activity: 1.5 hours
Faculty Co-Chairs
Jeffrey S. Heier, MD
Director, Retina Service
Director, Retina Research
Ophthalmic Consultants of Boston
Boston, MA
Arshad M. Khanani, MD, MA, FASRS
Clinical Associate Professor
University of Nevada, Reno School of Medicine
Managing Partner, Director of Clinical Research, Director of Fellowship
Sierra Eye Associates
Reno, NV
Target Audience
This activity has been designed to address the educational needs of comprehensive ophthalmologists and retina specialists. It may also benefit other clinicians who are involved in the care of patients with neovascular retinal diseases.
Educational Provider
This activity is provided by Paradigm Medical Communications, LLC. 
Supporter Acknowledgement
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Program Overview
Exciting new treatment advances offer viable alternatives to high-burden intravitreal vascular endothelial growth factor (VEGF) inhibitors for a wide range of patients with neovascular retinal diseases. Join our internationally renowned expert faculty as they discuss appropriate, evidence-based integration of novel agents into clinical practice using real-life case studies across several common disease states (neovascular age-related macular degeneration, diabetic macular edema, and macular edema secondary to retinal vein occlusion).
Learning Objectives
Upon completion of this activity, participants should be able to:
- Differentiate novel therapy from conventional intravitreal anti-VEGF therapy based on clinical trial data
- Evaluate data demonstrating differences in treatment and outcomes between patients with neovascular retinal diseases who are treated in the real world versus clinical trials
- Apply evolving clinical trial data and real-world data to determine treatment intervention for patients with neovascular retinal disease
Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA Continuing Education
PAs may claim a maximum of 1.50 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Hardware/Software Requirements
This accredited CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.
Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+
PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader
Technical Support
If you have any technical problems or playback issues, email us at contactus@paradigmmc.com.
Instructions for Participation
To receive a certificate of participation, participants must:
- Follow instructions to register or log in with your professional information and complete the preassessment
- View the online activity in its entirety
- Complete and submit the online postassessment and evaluation. You must answer 70% of the postassessment questions correctly to earn credit. You will have unlimited opportunities to successfully complete the postassessment
A certificate of participation will be available for download/printing immediately following your successful completion of the postassessment and evaluation.
For questions regarding CME credit, contact the Paradigm CME Department at cme@paradigmmc.com.
There are no fees for participating in this activity.
Disclosures of Relevant Financial Relationships
In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months.
All relevant relationships are identified and mitigated according to Paradigm policy prior to individuals assuming their roles, and are disclosed prior to learners’ engagement in the activity. Paradigm is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The content of this activity was independently reviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated.
Jeffrey S. Heier, MD
Consultant: 4D Molecular Therapeutics; Abro Pharmaceuticals; Adverum Biotechnologies, Inc.; AffaMed Therapeutics; AGTC; Akouos; Annexon Biosciences; Apellis Pharmaceuticals, Inc; AsclepiX Therapeutics; Aviceda Therapeutics; Bausch & Lomb; Biovisics Medical; Curacle Co Ltd; Exegenesis Bio; Genentech, Inc; Glaukos Corporation; Gyroscope Therapeutics Limited; ImmunoGen, Inc.; Iveric Bio, Inc; Janssen Pharmaceuticals, Inc; jCyte, Inc.; Kriya Therapeutics; Nanoscope Therapeutics; NGM Biopharmaceuticals; Notal Vision, Inc; Novartis; Ocular Therapeutix; Ocuphire Pharma, Inc; OcuTerra Therapeutics; OliX Pharmaceuticals, Inc; ONL Therapeutics; Outlook Therapeutics, Inc.; Perceive Biotherapeutics; Ray Therapeutics; Regeneron Pharmaceuticals Inc; REGENXBIO Inc; RetinAI Medical AG; Sanofi; Stealth BioTherapeutics Inc; Thea Pharma Inc; VanoTech
Research Funding: 4D Molecular Therapeutics; Annexon Biosciences; Apellis Pharmaceuticals, Inc; AsclepiX Therapeutics; Ashvattha Therapeutics; Bayer Corporation; Cognition Therapeutics; Curacle Co Ltd; Genentech, Inc; Gyroscope Therapeutics Limited; Iveric Bio, Inc; Janssen Pharmaceuticals, Inc; Kodiac Sciences Inc; NGM Biopharmaceuticals; Notal Vision; Novartis; OcuTerra Therapeutics; Perceive Biotherapeutics; Regeneron Pharmaceuticals Inc; REGENXBIO Inc
Stocks: Adverum Biotechnologies, Inc.; Aldeyra Therapeutics, Inc; Allegro Ophthalmics, LLC; Aviceda Therapeutics; DTx Pharma, Inc; jCyte, Inc.; Ocuphire Pharma, Inc; Ocular Therapeutix; RevOpsis Therapeutics; Vinci Pharmaceuticals, Inc; Vitranu, Inc.
Other (Board of Directors): Ocular Therapeutix
Arshad M. Khanani, MD, MA, FASRS
Consultant: 4D Molecular Therapeutics; AbbVie Inc; Adverum Biotechnologies, Inc; Aerie Pharmaceuticals, Inc; AGTC; Aldebaran Therapeutics, Inc; Apellis Pharmaceuticals, Inc; Arrowhead Pharmaceuticals, Inc; Aviceda Therapeutics; Bausch & Lomb; Broadwing Bio; Chengdu Kanghong Pharmaceutical Group Co, LTD; Clearside BioMedical; Exegenesis Bio Co; EyePoint Pharmaceuticals, Inc; F. Hoffmann-La Roche AG; Frontera Therapeutics, Inc.; Genentech, Inc; Gyroscope Therapeutics Limited; i-Lumen Scientific; Iveric Bio, Inc; Janssen Pharmaceuticals, Inc; Kartos Therapeutics, Inc; Kato Pharmaceuticals; Kodiak Sciences Inc; Kriya Therapeutics; Ocular Therapeutix, Inc; Oculis; OcuTerra Therapeutics; Olive BioPharma; Opthea; Oxurion NV; Nanoscope Therapeutics, Inc; Notal Vision, Inc; Novartis AG; Perfuse Therapeutics; PolyPhotonix Medical Ltd; Ray Therapeutics; RecensMedical Inc; Regeneron Pharmaceuticals Inc; REGENXBIO Inc; RevOpsis Therapeutics; Stealth BioTherapeutics Inc; Thea Pharma Inc; UNITY Biotechnology; Vial
Research Funding: 4D Molecular Therapeutics; Adverum Biotechnologies, Inc; Annexon, Inc; Apellis Pharmaceuticals, Inc; F. Hoffmann-La Roche AG; Genentech, Inc; Gyroscope Therapeutics Limited; Iveric Bio, Inc; Kodiak Sciences Inc; Neurotech Pharmaceuticals, Inc; NGM Biopharmaceuticals Inc; Novartis AG; Ocular Therapeutix, Inc; Oculis; OcuTerra Therapeutics; Opthea; Oxurion NV; REGENXBIO Inc; UNITY Biotechnology
Stocks: RevOpsis Therapeutics
Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies to disclose.
Independent peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.
Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.
Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.
Contact Us
If you have any questions or comments, please email us at contactus@paradigmmc.com.
© 2023 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.